Richard J. Heath
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Richard J. Heath has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Alberto S. Pappo
27 shared publications- Bonald Cavalcante Figueiredo
Instituto de Pesquisa Pelé Pequeno Príncipe, Curitiba 80250-060, PR, Brazil
27 shared publications Carlos Rodriguez-Galindo
27 shared publications- Emilia Modolo Pinto
Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN, USA
27 shared publications - Enzo Lalli
Institut de Pharmacologie Moléculaire et Cellulaire CNRS UMR7275, Inserm U1323, Université Côte d’Azur, 06560 Valbonne, France
27 shared publications - Geoffrey Neale
Hartwell Center, St. Jude Children’s Research Hospital, Memphis, USA
27 shared publications
Latest Publications
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from The Common Germline TP53-R337H Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model
Elevated levels of mutant p53 protein in the nucleus of low passage p53-R334H MEFs.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from The Common Germline TP53-R337H Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model
Elevated levels of mutant p53 protein in the nucleus of low passage p53-R334H MEFs.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from The Common Germline TP53-R337H Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model
Erastin treatment of early passage primary MEFs induced cell death in cells with mutant p53.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from The Common Germline TP53-R337H Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model
Erastin treatment of early passage primary MEFs induced cell death in cells with mutant p53.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from The Common Germline TP53-R337H Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model
Mdm2 Knockout Embryonic Lethality
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from The Common Germline TP53-R337H Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model
Mdm2 Knockout Embryonic Lethality
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from The Common Germline TP53-R337H Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model
Mutant p53-R334H is abnormally expressed and functionally impaired in vivo in response to DNA damage.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from The Common Germline TP53-R337H Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model
Mutant p53-R334H is abnormally expressed and functionally impaired in vivo in response to DNA damage.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from The Common Germline TP53-R337H Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model
Mutant p53-R334H is abnormally expressed and functionally impaired in vivo in response to DNA damage.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from The Common Germline TP53-R337H Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model
Mutant p53-R334H is abnormally expressed and functionally impaired in vivo in response to DNA damage.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from The Common Germline TP53-R337H Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model
The TP53-R337H founder mutation exists at a high frequency throughout southern Brazil and represents one of the most common germline TP53 mutations reported to date. It was identified in pediatric adrenocortical tumors in families with a low incidence of cancer. The R337H mutation has since been found in association with early-onset breast cancers and Li–Fraumeni syndrome (LFS). To study this variability in tumor susceptibility, we generated a knockin mutant p53 mouse model (R334H). Endogenous murine p53-R334H protein was naturally expressed at high levels in multiple tissues and was functionally compromised in a tissue- and stress-specific manner. Mutant p53-R334H mice developed tumors with long latency and incomplete penetrance, consistent with many human carriers being at a low but elevated risk for cancer. These findings suggest the involvement of additional cooperating genetic alterations when TP53-R337H occurs in the context of LFS, which has important implications for genetic counseling and long-term clinical follow-up.Significance:A p53-R334H knockin mouse serves as an important model for studying the most common inherited germline TP53 mutation (R337H) that is associated with variable tumor susceptibility.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from The Common Germline TP53-R337H Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model
The TP53-R337H founder mutation exists at a high frequency throughout southern Brazil and represents one of the most common germline TP53 mutations reported to date. It was identified in pediatric adrenocortical tumors in families with a low incidence of cancer. The R337H mutation has since been found in association with early-onset breast cancers and Li–Fraumeni syndrome (LFS). To study this variability in tumor susceptibility, we generated a knockin mutant p53 mouse model (R334H). Endogenous murine p53-R334H protein was naturally expressed at high levels in multiple tissues and was functionally compromised in a tissue- and stress-specific manner. Mutant p53-R334H mice developed tumors with long latency and incomplete penetrance, consistent with many human carriers being at a low but elevated risk for cancer. These findings suggest the involvement of additional cooperating genetic alterations when TP53-R337H occurs in the context of LFS, which has important implications for genetic counseling and long-term clinical follow-up.Significance:A p53-R334H knockin mouse serves as an important model for studying the most common inherited germline TP53 mutation (R337H) that is associated with variable tumor susceptibility.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from The Common Germline TP53-R337H Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model
Supplemental Materials and Methods and Supplementary Figure Legends
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from The Common Germline TP53-R337H Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model
Supplemental Materials and Methods and Supplementary Figure Legends
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from The Common Germline TP53-R337H Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model
Mouse Cohorts and Associated Pathology
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from The Common Germline TP53-R337H Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model
Mouse Cohorts and Associated Pathology